A study to compare parasagittal and transforaminal epidural block in patients with herpes zoster pain involving lumbosacral dermatomes

A Comparative Study Of Parasaggital Versus Transforaminal Epidural Block In Herpetic Neuralgia Involving Lumbosacral Dermatomes

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026898

Enrollment

Registered

2020-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G09- Sequelae of inflammatory diseasesof central nervous system

Interventions

Intervention1: parasaggital epidural block: parasaggital epidural block using triamcinolone acetonide 60mg in 3ml normal saline Control Intervention1: transforaminal epidural block: transforaminal epi

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients over 18 years of age. 2) ASA grade I and II. 3) Neuropathic pain of herpes zoster involving lumbosacral dermatomes. 4) Neuro-radiologic studies that rule out presence of any invasive lesion or disc related disease. 5) Willingness of patients to actively participate in this study.

Exclusion criteria

Exclusion criteria: 1) Patients age 75 years. 2) Patients receiving anticoagulants, aspirin, aspirin containing NSAIDs or hypersensitivity to local anaesthetic agents. 3) Patients with coagulopathies or prolonged bleeding time. 4) Patients with suspected disc herniation or radiculitis. 5) Patients with history of recent surgical procedure in lumbar spine within last 3 months. 6) Ongoing septicaemia as demonstrated by elevated white blood cells or infection overlying the entry area. 7) Uncontrolled psychiatric disorder or major depression or other severe medical illness. 8) Pregnant or lactating mothers. 9) Malingering or secondary gain.

Design outcomes

Primary

Measure	Time frame
Level of pain relief of the patients as assessed by Numeric Rating Scale (NRS)Timepoint: 6 weeks	—

Secondary

Measure	Time frame
Any complication such as pain, bleeding, infection occurring during and after the block were noted.Timepoint: 6 weeks;Overall improvement in quality of life of the patient as assessed by SF-12 score.Timepoint: 6 weeks;Pain and disability as assessed by Neuropathic Pain Symptom Inventory (NPSI). Timepoint: 6 weeks;Requirement of rescue analgesics on weekly basis: The patients were instructed to record number of doses of analgesic consumed per week for pain during the study period.Timepoint: 6 weeks	—

Measure

Time frame

Any complication such as pain, bleeding, infection occurring during and after the block were noted.Timepoint: 6 weeks;Overall improvement in quality of life of the patient as assessed by SF-12 score.Timepoint: 6 weeks;Pain and disability as assessed by Neuropathic Pain Symptom Inventory (NPSI). Timepoint: 6 weeks;Requirement of rescue analgesics on weekly basis: The patients were instructed to record number of doses of analgesic consumed per week for pain during the study period.Timepoint: 6 weeks

—

Countries

India

Contacts

Public ContactHammad Usmani

JNMCH, AMU, Aligarh

hammadusmani2002@gmail.com9897114190

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026